US Markets

Roche taps Eli Lilly executive as chief medical officer

Credit: REUTERS/Arnd Wiegmann

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

ZURICH, Aug 19 (Reuters) - Swiss drugmaker Roche Holding ROG.S on Monday named Eli Lilly LLY.N executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.

Horning will retire as of the end of 2019.

(Reporting by John Miller, Writing by Michael Shields. Editing by Jane Merriman)

((Michael.Shields@thomsonreuters.com; +41 58 306 7461; Reuters Messaging: michael.shields.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More